Lv11
38 积分 2023-08-08 加入
Targeting MET-mediated TKI resistance in EGFR-mutant NSCLC
1小时前
求助中
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
1小时前
已完结
呋喹替尼治疗晚期HER-2 阴性胃腺癌的效果观察
1个月前
已完结
A case report: enhanced somatostatin receptor expression in metastatic pancreatic neuroendocrine tumor following everolimus therapy
2个月前
已完结
中医药治疗呋喹替尼相关手足皮肤反应研究进展
2个月前
已完结
呋喹替尼致肿瘤患者蛋白尿发生率和总体风险的Meta分析
2个月前
已完结
基于FAERS数据库的呋喹替尼真实世界不良事件研究
2个月前
已完结
皖公网安备34019202002308
